Suivre
Ye Sheng
Ye Sheng
Adresse e-mail validée de astrazeneca.com - Page d'accueil
Titre
Citée par
Citée par
Année
Nanoparticle-Based Topical Ophthalmic Gel Formulation for Sustained Release of Hydrocortisone Butyrate.
Yang X, Thrnh HM, Agrahari V, Sheng Y, Pal D, Mitra AK
AAPS PharmSciTech., 2015
81*2015
Statistical design for formulation optimization of hydrocortisone butyrate-loaded PLGA nanoparticles
X Yang, S Patel, Y Sheng, D Pal, AK Mitra
Aaps PharmSciTech 15, 569-587, 2014
302014
Design of lipophilic prodrugs to improve drug delivery and efficacy.
MAK Mandal A, Patel M, Sheng Y
Curr Drug Targets, 2015
27*2015
Interaction of dipeptide prodrugs of saquinavir with multidrug resistance protein-2 (MRP-2): evasion of MRP-2 mediated efflux
R Jain, S Agarwal, NK Mandava, Y Sheng, AK Mitra
International Journal of Pharmaceutics 362 (1-2), 44-51, 2008
262008
Prodrug approach to improve absorption of prednisolone
Y Sheng, X Yang, D Pal, AK Mitra
International journal of pharmaceutics 487 (1-2), 242-249, 2015
182015
Dipeptide prodrug approach to evade efflux pumps and CYP3A4 metabolism of lopinavir
M Patel, Y Sheng, NK Mandava, D Pal, AK Mitra
International journal of pharmaceutics 476 (1-2), 99-107, 2014
72014
Stereoisomeric Prodrugs to Improve Corneal Absorption of Prednisolone: Synthesis and In Vitro Evaluation
Y Sheng, X Yang, Z Wang, AK Mitra
AAPS PharmSciTech 17, 718-726, 2016
52016
Uptake and bioconversion of stereoisomeric dipeptide prodrugs of ganciclovir by nanoparticulate carriers in corneal epithelial cells
X Yang, Y Sheng, A Ray, SJ Shah, HM Trinh, D Pal, AK Mitra
Drug Delivery 23 (7), 2532-2540, 2016
42016
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–8